Thomas Malley - 15 Jun 2023 Form 4 Insider Report for BeiGene, Ltd. (ONC)

Reporting relationship: Director
Issuer ticker: ONC
Reported as of: 15 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Jun 2023, 19:00:29 UTC
Prior SEC filing: 08 Jun 2023
Next SEC filing: 21 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Qing Nian, as Attorney-in-Fact

Key filing fact

Thomas Malley filed Form 4 for BeiGene, Ltd. (ONC) on 20 Jun 2023.

Key facts

This page summarizes Thomas Malley's Form 4 filing for BeiGene, Ltd. (ONC).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 20 Jun 2023, 19:00.

Change

Previous filing in this sequence was filed on 08 Jun 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BGNE transaction

Ordinary Shares

Award

Transaction value: $0
Shares: +12,922
Change %: +38%
Price: $0.000000
Shares after: 46,696
Date: 15 Jun 2023
Ownership: Direct
Footnotes: F1

BGNE holding

American Depositary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 30,000
Date: 15 Jun 2023
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BGNE transaction Derivative

Share Option (Right to Buy)

Award

Transaction value: $0
Shares: +26,975
Change %
Price: $0.000000
Shares after: 26,975
Date: 15 Jun 2023
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 26,975
Exercise price: $16.41
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The restricted share units were granted under the Company's Independent Director Compensation Policy, as amended.

Footnote F2

Each American Depositary Share represents 13 ordinary shares.

Footnote F3

The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.

Footnote F4

The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. The option was granted under the Company's Independent Director Compensation Policy, as amended.